-
Taxonomy & unit
-
us-gaap: USD
-
Description
-
Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.
-
Summary
-
Xenon Pharmaceuticals Inc. quarterly/annual Deferred Income Tax Expense (Benefit) history and growth rate from Q1 2018 to Q1 2024.
- Xenon Pharmaceuticals Inc. Deferred Income Tax Expense (Benefit) for the quarter ending March 31, 2024 was $403K, a 39.9% increase year-over-year.
- Xenon Pharmaceuticals Inc. annual Deferred Income Tax Expense (Benefit) for 2023 was -$292K, a 564% decline from 2022.
- Xenon Pharmaceuticals Inc. annual Deferred Income Tax Expense (Benefit) for 2022 was -$44K, a 176% decline from 2021.
- Xenon Pharmaceuticals Inc. annual Deferred Income Tax Expense (Benefit) for 2021 was $58K.
Deferred Income Tax Expense (Benefit), Quarterly (USD)
Deferred Income Tax Expense (Benefit), YoY Quarterly Growth (%)